Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
5 studies found for:    VAL--083
Show Display Options
Rank Status Study
1 Recruiting Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma
Conditions: Glioma;   Glioblastoma;   Glioblastoma Multiforme;   GBM;   Brain Cancer
Intervention: Drug: VAL-083, Dianhydrogalactitol
2 Not yet recruiting Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Conditions: Glioma;   Glioblastoma;   Glioblastoma Multiforme;   GBM;   Brain Cancer
Intervention: Drug: VAL-083 (Dianhydrogalactitol)
3 Completed Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Conditions: Glioma;   Glioblastoma;   Glioblastoma Multiforme;   GBM;   Brain Cancer
Intervention: Drug: VAL-083 (Dianhydrogalactitol)
4 Available Expanded Access to VAL-083
Condition: Cancer
Intervention: Drug: VAL-083
5 Not yet recruiting VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
Conditions: Glioblastoma Multiforme;   Glioblastoma;   Glioma;   GBM;   Brain Cancer
Interventions: Drug: VAL-083, Dianhydrogalactitol;   Drug: Physician's Choice of Salvage Therapy - temozolomide;   Drug: Physician's Choice of Salvage Therapy - lomustine;   Drug: Physician's Choice of Salvage Therapy - carboplatin

Study has passed its completion date and status has not been verified in more than two years.